Latest Breaking News On - Christian ottensmeier - Page 6 : comparemela.com

acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesChristian ottensmeierMasamitsu kitaseChristophe le tourneauLe tourneauAlexandra martinezJean pierre delordTransgene euronextInstitut curieYujie zhaoAlessandro rivaUniversity of liverpoolLife science divisionNec ai drug development businessHead of surgical department

Transgene provides business update and Q1 2023 financial position

Transgene provides business update and Q1 2023 financial position Dr. Alessandro Riva, MD, appointed as the Company’s Chairman and CEO to accelerate the development of Transgene’s innovative immunotherapy portfolio New clinical data to be communicated in Q2 2023 on TG4001, TG4050.

Ben brahimCarol stuckleyChristian ottensmeierAlessandro rivaPedro romeroJohnc bellUniversity of liverpoolJolla institute for immunologyMerck coCompany board of directorsEuronext parisProfessor christian ottensmeierTasly biopharmaceuticalsCombined general meeting

Transgene provides business update and Q1 2023 financial position

Transgene provides business update and Q1 2023 financial position
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Pedro romeroAlessandro rivaChristian ottensmeierCarol stuckleyBen brahimJohnc bellLucie larguierTransgene euronextCorporate communicationsCompany board of directorsJolla institute for immunologyMerck coUniversity of liverpoolEuronext parisProfessor christian ottensmeierTasly biopharmaceuticals

Transgene provides business update and Q1 2023 financial position

10.05.2023 - Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today provides a business update, including its financial position as of March 31, 2023. Key . Seite 1

Christian ottensmeierJolla institute for immunologyUniversity of liverpoolProfessor christian ottensmeier

New Data Shows Promising Immunogenecity & Efficacy Profile of Transgene & NEC s Individualized Cancer Vaccine TG4050

New Data Showing that Transgene and NEC's Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023 - New Phase I data confirm promising immunogenicity and efficacy profile of TG4050, an .

United statesUnited kingdomAlexandra martinezMasamitsu kitaseTransgene euronextInstitut curieChristian ottensmeierChristophe le tourneauJean pierre delordBen brahimLe tourneauYujie zhaoUniversity of liverpoolNec ai drug development businessHealthcare life sciences businessJolla institute for immunology